TIDMKNB

RNS Number : 1660C

Kanabo Group PLC

08 June 2023

8 June 2023

Kanabo Group plc

("Kanabo", the "Group" or the "Company")

Notice of Annual General Meeting

Kanabo Group plc (LSE: KNB), the patient focused healthcare technology and medicinal cannabis company, announces the Notice of Annual General Meeting ("Notice of Meeting") has now been published. The document has been posted to shareholders and is now available to download from the Company's website: https://www.kanabogroup.com/

The Company's Annual General Meeting is scheduled to be help on Friday, 30 June 2023 at Asserson Law Offices of Central Court, 25 Southampton Buildings, Holborn, London WC2A 1AL. The meeting will commence at 1.00 p.m.

The voting results of all resolutions put before the 2023 AGM will be announced shortly afterwards.

Enquiries:

 
Kanabo Group plc                                       via Vigo Consulting 
 Avihu Tamir, Chief Executive Officer                   +44 (0)20 7390 0230 
 Assaf Vardimon, Chief Financial Officer 
 Ian Mattioli, Non-Executive Chair of the Board 
Peterhouse Capital Ltd (Financial Adviser 
 and Broker) 
 Eran Zucker / Lucy Williams / Charles Goodfellow      +44 (0)20 7469 0930 
 
Vigo Consulting (Financial Public Relations/Investor 
 Relations) 
 Jeremy Garcia / Fiona Hetherington / Verity 
 Snow                                                   +44 (0)20 7390 
 kanabo@vigoconsulting.com                               0230

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAUPUAGQUPWGQR

(END) Dow Jones Newswires

June 08, 2023 12:20 ET (16:20 GMT)

Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Kanabo.
Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Kanabo.